Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-3 eplerenone + dapagliflozin study)
2017-004641-25Phase 3Active
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eplerenone, dapagliflozin in proteinuric kidney disease, chronic kidney disease (CKD), hypertension (HTN), sponsored by University Medical Center Groningen. Started Apr 2019; status: active.
02
Drugs
eplerenonedapagliflozin
03
Conditions
proteinuric kidney diseasechronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on 2017-004641-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004641-25.